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Abstract
Nevirapine is one of the most extensively prescribed antiretroviral drugs worldwide. However, a
concern is increased risk for severe toxicity when antiretroviral-naive individuals with higher CD4
T-cell counts initiate nevirapine-containing regimens. Several genetic variants are associated with
nevirapine toxicities. The authors used data from a previous study to anticipate potential
consequences of genetic screening to prevent nevirapine adverse events. That study enrolled
cohorts of African, Asian and European descent in 11 countries, including 276 patients who had
experienced severe cutaneous and/or hepatic adverse events with nevirapine-containing regimens
and 587 matched nevirapine-tolerant controls. Associations were identified with HLA-Cw*04,
HLA-B*35, HLA-DRB*01 and CYP2B6 516G>T (rs3745274); however, positive predictive
values for these genetic markers were low, and most nevirapine-associated adverse events
occurred in patients without these markers. Unless better genetic predictors are identified,
nevirapine toxicity is best avoided by continuing to follow current prescribing guidelines that are
based largely on CD4 T-cell criteria.
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Overview of nevirapine & its pharmacology
The non-nucleoside reverse transcriptase inhibitor nevirapine is one of the most extensively
prescribed antiretroviral drugs worldwide. An immediate-release (IR) formulation was first
approved for clinical use in 1996 and is now included among the acceptable multidrug
regimens as initial therapy for HIV-1 infection in the USA [101]. In resource-limited
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countries, nevirapine was among the first drugs to become generally available for treating
HIV-1 infection, and a generic coformulation of IR nevirapine plus two nucleoside
analogues continues to be a corner stone of therapy in many countries. In 2011, a once-daily
extended-release (ER) formulation of nevirapine was approved for use in combination
regimens for treating HIV-1 infection in adults [102]. Nevirapine has played an important
role in reducing mother-to-child transmission of HIV-1 globally, with a single intrapartum
dose decreasing vertical transmission approximately threefold [1].
Nevirapine has excellent oral bioavailability and distributes widely throughout the body to
sites that harbor HIV-1, including the brain. There is considerable interindividual variability
in nevirapine pharmacokinetics. For example, in a study of 170 HIV-infected Cambodians,
trough plasma nevirapine concentrations at steady-state varied sevenfold, from
approximately 2000 to 14000 ng/ml (excluding individuals with who were likely
nonadherent) [2]. Inactivation of nevirapine occurs primarily through hepatic CYP2B6 and
less so through CYP3A and other isoforms; nevirapine induces its own metabolism (i.e.,
autoinduction). To decrease the likelihood of rash during treatment initiation, it is
recommended that nevirapine be dosed at 200 mg once daily for the first 14 days, then
increased to full dose (200 mg twice daily with IR nevirapine, 400 mg once daily with ER
nevirapine). Despite the steady-state plasma half-life of approximately 25–30 h of IR
nevirapine [103], after the first 14 days it is generally given twice daily owing to concern
about possible hepatotoxicity with once-daily dosing [3], although it is not clear that
increased plasma nevirapine concentrations cause increased hepatotoxicity. There has been a
reported association between nevirapine pharmacokinetics and rash, with 50% higher
likelihood of rash for every 20% decrease in plasma nevirapine clearance [4]. The risk of
hepatotoxicity with 400-mg once-daily dosing appears to be low when CD4 T-cell
thresholds (see below) and 14-day dosage escalation guidelines are followed [5]. One study
showed safety of switching from 200 mg twice daily to 400 mg once daily after at least 12 to
18 weeks of therapy [6]. With the ER formulation, 400 mg once daily should begin
immediately after the aforementioned 14-day lead in.
Nevirapine toxicity & human genetics
When nevirapine was first approved for clinical use, the predisposition of some individuals
to experience severe toxicity was not appreciated, perhaps because those at greatest risk for
adverse events (i.e., HIV-infected individuals with higher CD4 T-cell counts) were under-
represented in early clinical trials and relatively few HIV-negative individuals receive
repeated doses of investigational drugs during Phase I clinical trials. Toxicity became
apparent, however, when repeated doses of nevirapine- containing regimens were initiated in
HIV-infected patients with higher CD4 T-cell counts [7]. In a clinical trial of the nucleoside
analogue emtricitabine (FTC-302 study; Triangle Pharmaceuticals) performed in South
Africa, participants with lower plasma HIV-1 RNA concentrations (i.e., higher CD4 T-cell
counts) were stratified to receive nevirapine-containing regimens. In that study, 17% of
nevirapine recipients experienced grade 3 or 4 liver toxicity, and two died of hepatic failure
[7]. The toxicity and other experiences established that higher CD4 T-cell count at
nevirapine initiation, female gender and antiretroviral treatment-naive status were associated
with increased risk for toxicity [8]. Such data prompted a change in product labeling,
recommending that nevirapine-containing regimens not be initiated in adult females with
>250 CD4 T cells/mm3 or in adult males with >400 CD4 T cells/mm3 [101,103]. Severe
hepatotoxicity occurs predominantly among patients with higher CD4 T-cell counts who
initiate therapy with plasma HIV-1 RNA <50 copies/ml. Increased risk for toxicity based on
CD4 T-cell count thresholds has not been detected in patients with plasma HIV-1 RNA <50
copies/ml who then switch to nevirapine-containing regimens [104].
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Before its potential for adverse reactions in immunocompetent individuals was recognized,
nevirapine seemed an attractive option as postexposure prophylaxis among HIV-negative
healthcare workers following occupational exposures to blood and body fluids. In this
setting, nevirapine-containing regimens were generally prescribed for 4–6 weeks. Cases of
severe hepatotoxicity, however, occurred when prescribed for postexposure prophylaxis, at
least one of which required liver transplantation [9]. This led to nevirapine being
contraindicated for use during postexposure prophylaxis [103].
Adverse reactions with nevirapine occur almost exclusively within the first several weeks of
therapy and primarily affect the liver and/or skin. Some patients experience only skin and
others only liver involvement, while others experience both. Particularly severe reactions
tend to be multisystem in nature with concomitant fever, hepatitis, and skin rash (sometimes
culminating in Stevens–Johnson syndrome). Early reports of skin rash and fever strongly
suggested that many nevirapine reactions were immune-mediated.
A number of studies have sought to identify immunogenetic predictors of nevirapine adverse
events. A seminal study from the Western Australia HIV cohort implicated HLA-
DRB1*01:01 in hepatic adverse events [10]. Among 26 patients (25 white patients) who
experienced alanine transaminase elevation, fever and/or rash with nevirapine and in 209
controls, HLA-DRB1*01:01 was significantly associated with hepatic/systemic reactions but
not with isolated skin events. The association was only apparent in patients who initiated
nevirapine with at least 25% CD4 T cells. More recently, an association was reported
between HLA-DRB1*01:02 and nevirapine-associated hepatic adverse events in the
aforementioned protocol FTC-302, which predominantly enrolled black patients [11]. By
contrast, studies in Sardinia and Japan implicated HLA-Cw*08 in hepatotoxicity [12,13].
Regarding nevirapine-associated cutaneous reactions, studies in Thailand implicated HLA-
Cw*04:01 and HLA-B*35:05 [14,15]. Among 147 patients with such adverse events and in
185 nevirapine-tolerant controls, Chantarangsu et al. reported associations with HLA-
B*35:05, HLA-Cw*04:01 and the HLA-Cw*04:01–HLA-B*35:05 haplotype [14].
Similarly, Likanonsakul et al. found an association between HLA-Cw*04 and skin adverse
events among 39 patients and 60 controls in Thailand [15].
Few studies have explored relationships between nevirapine toxicity and genes involved in
drug metabolism and transport. Regarding hepatic adverse events, analyses of populations
from South Africa (i.e., protocol FTC-302) [16], Mozambique [17] and the USA [18] each
suggested a very modest association with ABCB1 (which encodes the membrane transporter
P-glycoprotein) position 3435C>T (rs1045642), but not with the CYP2B6 position 516 G>T
(rs3745274) loss-of-function variant that is known to predict decreased plasma clearance of
nevirapine [19–21]. As discussed below, only recently has a drug metabolism gene variant
been implicated in nevirapine-associated adverse events [22].
A study across patient ancestries & toxicity phenotypes
Inconsistencies among previous genetic association studies of nevirapine may have
reflected, at least in part, inconsistent adverse event phenotypes and different geographic
regions of ancestry. Results were recently published from a retrospective case-controlled
study with prospective DNA collection [22,105]. The study by Yuan et al. was designed to
separately identify genetic predictors for cutaneous and hepatic adverse events and to
separately characterize these associations among cohorts of Asian, European and African
descent (hereafter called Asian, white and black patients). Participants were at least 18 years
of age, HIV-1 infected, and had a recent CD4 T-cell count of >150 cells/mm3 within 6
months before starting nevirapine-containing regimens [22]. Patients had experienced severe
(grade 3 or 4), symptomatic cutaneous, and/or hepatic adverse events within the first 8
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weeks of initiating nevirapine, while controls had tolerated nevirapine for at least 18 weeks.
Patients and controls were matched on CD4 T-cell count, gender and self-reported race (for
details of study design [22]). The study enrolled 889 participants at 76 research sites in 11
countries, including 276 evaluable patients (175 with cutaneous adverse events and 101 with
hepatic adverse events) and 587 evaluable controls. Baseline CD4 T-cell counts were >250
and >400 cells/mm3 in 70 and 49% of females and males, respectively.
Yuan et al. found significant associations between HLA-Cw*04 and cutaneous adverse
events among all study participants, and especially among black and Asian patients [22].
HLA-B*35 was strongly associated with cutaneous adverse events among Asians (of whom
74% were Thai), but only weakly among white patients. Among Asians the odds ratio for
cutaneous adverse events was increased among those carrying both HLA-Cw*04 and HLA-
B*35. Regarding drug metabolism and transporter gene variants, associations were noted
between CYP2B6 516G>T (rs3745274) and cutaneous adverse events among black and
white patients, with a weak trend among Asians. Patients carrying both CYP2B6
516(rs3745274) TT and HLA-Cw*04 were at increased risk among the total population and
among black and Asian patients analyzed separately. HLA-DRB1*01 was significantly
associated with hepatic adverse events among white patients; however, this allele was
infrequent among black patients and rare among Asians. No association was reported
between CYP2B6 516G>T (rs3745274) and hepatic adverse events or between the
previously implicated ABCB1 3435C>T (rs1045642) variant [16–18] and either cutaneous
or hepatic adverse events. In summary, this study confirmed associations between HLA-
B*35, HLA-Cw*04 and skin adverse events previously reported among Thai cohorts
[14,15], extended the HLA-Cw*04 association to black and white patients, confirmed the
association between HLA-DRB1*01 and hepatic adverse events previously reported among
white patients [10] and subsequently among black patients [11], and identified a novel
association between CYP2B6 516G>T (rs3745274) and cutaneous adverse events.
The study by Yuan et al. had several limitations [22]. Because cases and controls were
matched on CD4 T-cell count, a post hoc analysis did not demonstrate a significant
contribution of CD4 T-cell count to adverse event risk. Important HLA and non-HLA
polymorphisms may have been found with more extensive (e.g., genome-wide) analyses.
High-resolution (e.g., four-digit) HLA typing may have increased specificities for at least
some associations identified; however, this would probably not have increased sensitivity.
General considerations for human genetic testing in clinical care
All medical disciplines are considering how best to integrate genetic knowledge into clinical
care so as to improve health outcomes (i.e., personalized medicine). Many issues regarding
logistics and costs of translating any new genetic test into clinical practice are complex. The
field will be increasingly influenced (if not driven) by technologic advances in both
genomics and medical informatics. For example, in resource-affluent settings, extensive data
regarding each patient's genome may soon be housed in their electronic medical record, with
informatics-intensive medical decision support being used to inform every prescribing
decision. Although to date there are very few situations where human genetic testing is
clearly indicated to guide prescribing (e.g., HLA-B*57:01 screening to prevent abacavir
hypersensitivity [23,24,101]), it may soon be routine for patients to have access to vast
amounts of data regarding variants in their own genomes. In such a scenario, issues that may
now seem daunting related to testing for individual genetic variants may become irrelevant
(i.e., assay cost per variant if high-throughput assays are used), or may be addressed across
disciplines (e.g., informatics solutions that integrate genomic data into clinical decision-
making). However, regardless of such advances, foundational principles to consider risks
and benefits of new laboratory tests will still apply.
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The utility of any genetic test to inform clinical care depends upon inherent performance
characteristics of the test, the prevalence of the condition in the population to whom the test
will be offered, and whether the new test substantially improves clinical decision-making
over readily available nongenetic information. Of particular relevance to nevirapine, severe
adverse events occur almost exclusively among individuals who initiate therapy at higher
CD4 T-cell counts and are therefore the patients who may most benefit from genetic
screening. Other considerations are availability and relative cost of antiretroviral alternatives
to nevirapine. Genetic testing would be most attractive if alternative agents are either
unavailable or are cost prohibitive.
In resource-abundant countries, several factors argue strongly against using genetic
screening to prevent nevirapine toxicity. Because CD4 T-cell count data are routinely
available before initiating therapy, clinicians can readily identify patients with higher CD4
T-cell counts in whom nevirapine should not be initiated. Among such individuals various
alternatives are available for nevirapine, including HIV-1 protease inhibitors, integrase
inhibitors and other non-nucleoside reverse transcriptase inhibitors. Furthermore, cost
differences between nevirapine and some other antiretrovirals are not profound. For
example, in 2012 the average wholesale price in US$ for 1 month of therapy (including
tenofovir/emtricitabine as the nucleoside component) are as follows: nevirapine-ER US
$2060; efavirenz US$2081; rilpivirine US$2196; lopinavir/ritonavir US$2332; raltegravir
US$2598; atazanavir/ritonavir US$2961; and darunavir/ritonavir US$3225. Given these
considerations and the devastating implications of even a single life-threatening adverse
event that could have been avoided, any genetic screening test would have to identify
virtually every individual who is predisposed to severe nevirapine-associated reactions (as
HLA-B*57:01 does for abacavir hypersensitivity [23,24]). As discussed below, available
data does not support such robust test performance for nevirapine genetic predictors.
In resource-limited countries, many considerations are the same as in resource-abundant
countries; however, they may vary by country. Many, if not all, care providers in resource-
limited countries have access to CD4 T-cell count data before initiating HIV-1 therapy and
can therefore identify patients at greatest risk for nevirapine adverse events. Until recently,
WHO guidelines recommended that initiation of HIV-1 therapy be limited to individuals
with <200 CD4 T cells/mm3, with some exceptions. Recent data from Port-au-Prince, Haiti,
showing improved outcomes when HIV-1 therapy is started at higher CD4 T-cell counts
[25] heightens the potential value of genetic screening for nevirapine. In resource-limited
countries, alternatives are available for nevirapine (e.g., efavirenz or lopinavir/ritonavir).
However, drug acquisition cost for IR nevirapine may be far less than for protease
inhibitors, and there is concern that efavirenz may cause fetal harm during the first trimester
of pregnancy [106]. Given these competing concerns, it is conceivable that public health
benefits of genetic screening, even with a test that is far from perfect, may be deemed to
outweigh individual risks in some resource-limited countries; however, given the challenges
in implementing human genetic testing, public health benefits would have to be substantial.
Sensitivity, specificity & clinical consequences of genetic testing with
nevirapine
The study by Yuan et al. provides empiric data with which to consider the potential utility of
genetic screening for nevirapine [22]. Sensitivities and specificities (as well as positive and
negative likelihood ratios)of genetic markers of cutaneous and liver adverse reactions from
that study stratified by population are shown in Table 1. These markers, either alone or in
combination, were not particularly sensitive, and 95% CI bounds around each sensitivity
estimate were quite broad. For example, among individuals with cutaneous adverse events,
HLA-Cw*04 was only present in 35, 56 and 34% of Asian, black and white patients,
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respectively. Thus two-thirds of Asian and white patients and one-half of black patients with
severe cutaneous adverse events lacked HLA-Cw*04. Similarly, among individuals with
cutaneous adverse events, homozygosity for CYP2B6 516 TT was only present in 19, 57
and 15% of Asian, black and white patients, respectively. Sensitivities were also low for
HLA-B*35, either alone or with concomitant HLA-Cw*04 and for skin adverse events when
considering various combinations of CYP2B6 516G>T (rs3745274) with HLA-Cw*04
(latter data not shown). For hepatic adverse events, HLA-DRB1*01 was similarly
insensitive. Only 44% of white patients with hepatic adverse events carried this allele, along
with an even lower proportion of Asian and black patients. Specificities for some of these
genetic markers were relatively high, at least in part driven by very low allelic frequencies in
some populations. Among Asians, the specificity of concomitant HLA-B*35 with HLA-
Cw*04 was 99%.
While sensitivities and specificities are informative, positive and negative predictive values
better describe the potential clinical utility of genetic testing. The matched case-control
design used by Yuan et al. precludes direct calculation of positive and negative predictive
values. This study, however, may be used to estimate these parameters if we make
assumptions about population risk prevalence and may provide insight into consequences if
genetic testing were to be implemented. To accomplish this we considered hypothetical
populations of 1000 individuals, all of whom initiate nevirapine-containing regimens at
higher CD4 T-cell counts. Within each population we considered two hypothetical
(admittedly, somewhat arbitrary) risk proportions – without genetic screening either 5 or
20% of individuals would experience severe nevirapine adverse reactions (the latter
approximates the 17% in protocol FTC-302 [22]). In the vast majority of genetic screening
scenarios, not only would the number of missed adverse events far exceed those averted, but
the number of patients needlessly avoiding nevirapine would be substantial (Table 2). For
example, genetic screening for HLA-Cw*04 in a hypothetical population of 1000 Asians
with a hypothetical 20% likelihood of cutaneous adverse events would prevent
approximately 70 cutaneous adverse events; however, approximately 130 cutaneous adverse
events would still occur, approximately 211 patients would have to avoid nevirapine and
three patients would have to avoid nevirapine unnecessarily for each event prevented. As
noted above, there is expected to be little or no benefit of genetic testing among individuals
who initiate nevirapine-containing regimens at low CD4 T-cell counts and who are therefore
at low risk for severe adverse events.
Conclusion
There are caveats with estimating the utility of genetic screening based on available data. All
the above considerations are based on data with IR nevirapine and may therefore not
translate directly to the ER formulation. The toxico-genetic association between CYP2B6
and cutaneous adverse events suggests that nevirapine concentration–time profiles may be
relevant [22]. It is therefore possible that some adverse events would be less likely with the
new ER formulation, which has a smoother plasma concentration–time profile. The lack of a
`gold standard' to confirm which adverse events are definitely caused by nevirapine makes it
more difficult to prove clinical benefit of any genetic test. By comparison, for abacavir
hypersensitivity reactions, the use of patch testing for immunologic confirmation played an
important part in demonstrating the clinical utility of HLA-B*57:01. Without abacavir patch
testing, the sensitivity of HLA-B*57:01 for clinically diagnosed hypersensitivity reactions
was 45.5%, but increased to 100% with patch testing [23]. Work to identify clinically useful
genetic predictors of nevirapine-associated adverse events should continue.
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Continued research may identify better genetic predictors of nevirapine adverse events,
which could improve positive and negative predictive values accordingly. It would be
particularly helpful if genetic variants could predict the most severe, life-threatening adverse
events. In this regard, although two individuals died of hepatic failure in protocol FTC-302,
there were other individuals in whom transaminase elevations resolved despite continued
dosing [7]. A double-blind randomized clinical trial in Thailand is prospectively testing the
use of genetic screening to prevent nevirapine-associated cutaneous side effects [107]. If
clinically useful genetic predictors of nevirapine-associated adverse events are found, novel
strategies to implement genetic testing in resource-limited countries may be warranted.
Acknowledgments
The investigators and personnel of the Nevirapine Toxicogenomics Study Team can be found in the SUPPLEMENTARY
MATERIAL (see www.futuremedicine.com/doi/suppl/10.2217/PME.12.82).
Funding has been provided by the National Institute of Allergy and Infectious Diseases (NIAID; grants AI077505
and AI54999 to DW Haas; grant 5 U19 AI053741-07 to K Ruxrungtham); National Research University (NRU)
project of CHE (grant HR1161A to K Ruxrungtham); the Ratchadaphiseksomphot Endowment Fund, Thailand; the
Professional Researcher Strengthen Grant from the National Science and Technology Development Agency
(NSTDA), BIOTEC; and senior researcher scholar from Thai Research Fund, Thailand (grant to K Ruxrungtham).
DW Haas has been principal investigator on research grants to Vanderbilt University from Boehringer Ingelheim,
Merck & Co. and Gilead Sciences. P Mootsikapun received research grants from Boehringer Ingelheim and
Janssen-Cilag and honoraria, educational grants and travel grants from Abbott, Bristol-Myers Squibb, Janssen-
Cilag, Merck Sharp & Dohme Corp. and Tibotec. K Ruxrungtham received speaker honoraria, educational or
research grant support from Abbott, Gilead, Bristol-Myers Squibb, Merck, Roche, Jensen-Cilag, GlaxoSmithKline,
Tibotec and the governmental pharmaceutical organization. D Podzamczer received research grants and/or
honoraria for advisories and/or conferences from Boehringer Ingelheim, GlaxoSmithKline, Viiv, Pfizer, Bristol-
Myers Squibb, Abbott, Gilead, Janssen and Merck.
No writing assistance was utilized in the production of this manuscript.
References
Papers of special note have been highlighted as:
■ of interest
■ of considerable interest
1. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared
with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-
month follow-up of the HIVNET 012 randomised trial. Lancet. 2003; 362:859–868. [PubMed:
13678973]
2. Chou M, Bertrand J, Segeral O, et al. Population pharmacokinetic–pharmacogenetic study of
nevirapine in HIV-infected Cambodian patients. Antimicrob. Agents Chemother. 2010; 54:4432–
4439. [PubMed: 20696882]
3. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with
regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a
randomised open-label trial, the 2NN study. Lancet. 2004; 363:1253–1263. [PubMed: 15094269]
4. Dong BJ, Zheng Y, Hughes MD, et al. Nevirapine pharmacokinetics and risk of rash and hepatitis
among HIV-infected sub-Saharan African women. AIDS. 2012; 26:833–841. [PubMed: 22301417]
5. Soriano V, Arastéh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with
tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN
trial. Antivir. Ther. 2011; 16:339–348. [PubMed: 21555816]
Haas et al. Page 7













6. Podzamczer D, Olmo M, Sanz J, et al. Safety of switching nevirapine twice daily to nevirapine once
daily in virologially suppressed patients. J. Acquir. Immune Defic. Syndr. 2009; 50:390–396.
[PubMed: 19214120]
7. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hapatotoxicity associated with nevirapine use in
HIV-infected subjects. J. Infect. Dis. 2005; 191:825–829. [PubMed: 15717255] ■ Describes a
prospective clinical trial in which a high proportion of patients who initiated nevirapine-containing
regimens at relatively high CD4 T-cell counts experienced hepatotoxicity.
8. Leith J, Piliero P, Storfer S, Mayers D, Hinzmann R. Appropriate use of nevirapine for long-term
therapy. J. Infect. Dis. 2011; 192:545–546. [PubMed: 15995971]
9. Centers for Disease Control. Serious adverse events attributed to nevirapine regimens for
postexposure prophylaxis after HIV exposure-worldwide, 1997–2000. MMWR Morb. Mortal. Wkly
Rep. 2001; 49:1153–1155. [PubMed: 11198946]
10. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with
HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS. 2005; 19:97–99. [PubMed:
15627041] ■ The first study to show an association between an HLA type and increased risk of
nevirapine hypersensitivity reactions.
11. Phillips, E.; Bartlett, JA.; Sanne, I., et al. Associations between HLA-DRB1*0102, HLA-B*5801
and hepatotoxicity in patients who initiated nevirapine-containing regimens in South Africa.
Presented at: 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA.
27 February–2 March 2011;
12. Gatanaga H, Yazaki H, Tanuma J, et al. HLA-Cw8 primarily associated with hypersensitivity to
nevirapine. AIDS. 2005; 21:264–265. [PubMed: 17197830]
13. Littera R, Carcassi C, Masala A, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian
HIV patients. AIDS. 2005; 20:1621–1626. [PubMed: 16868443]
14. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLA-B*3505 allele is a strong predictor
for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet.
Genomics. 2009; 19:139–146. [PubMed: 19104471]
15. Likanonsakul S, Rattanatham T, Feangvad S, et al. HLA-Cw*04 allele associated with nevirapine-
induced rash ijn HIV-infected Thai patients. AIDS Res. Ther. 2009; 6:22. [PubMed: 19845952]
16. Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated
hepatotoxicity: an adult AIDS clinical trials group collaboration. Clin. Infect. Dis. 2006; 43:783–
786. [PubMed: 16912957]
17. Ciccacci C, Borgiani P, Ceffa S, et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a
retrospective study in a population from Mozambique. Pharmacogenomics. 2010; 11:23–31.
[PubMed: 20017669]
18. Ritchie MD, Haas DW, Motsinger AA, et al. Drug transporter and metabolizing enzyme gene
variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin. Infect. Dis. 2006;
43:779–782. [PubMed: 16912956]
19. Chantarangsu S, Cressey TR, Mahasirimongkol S, et al. Influence of CYP2B6 polymorphisms on
the persistence of plasma nevirapine concentrations following a single intra-partum dose for the
prevention of mother to chilld transmission in HIV-infected Thai women. J. Antimicrob.
Chemother. 2009; 64:1265–1273. [PubMed: 19812066]
20. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and
intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.
Pharmacogenet. Genomics. 2005; 15:1–5. [PubMed: 15864119] ■ First study to show an
association between a CYP2B6 polymorphism and plasma pharmacokinetics of nevirapine.
21. Saitoh A, Sarles E, Capparelli E, et al. CYP2B6 genetic variants are associated with nevirapine
pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007; 21:2191–2199.
[PubMed: 18090046]
22. Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic
adverse events among populations of African, Asian, and European descent. AIDS. 2011;
25:1271–1280. [PubMed: 21505298] ■ Retrospective, case–control study involving Asian, black
and white subjects, which demonstrated that HLA types associated with cutaneous adverse events
Haas et al. Page 8













differed from those associated with liver toxicity, and showed that CYP2B6 516G>T was
associated with cutaneous but not liver events.
23. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N.
Engl. J. Med. 2008; 358:568–579. [PubMed: 18256392]
24. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker
for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect.
Dis. 2008; 46(7):1111–1118. [PubMed: 18444831]
25. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiviral therapy for HIV-infected
adults in Haiti. N. Engl. J. Med. 2010; 363(3):257–265. [PubMed: 20647201]
26. Jaynes, ET. Confidence intervals vs Bayesian intervals. In: Harper, WL.; Hooker, CA., editors.
Foundations of Probability Theory, Statistical Inference, and Statistical Theories of Science. Vol.
Volume II. D Reidel Publishing Co.; Dordrecht, The Netherlands: 1976. p. 175-257.
Websites
101. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of
antiretroviral agents in HIV-1-infected adults and adolescents. www.aidsinfo.nih.gov/
ContentFiles/AdultandAdolescentGL.pdf
102. Nevirapine XR prescribing information. http://bidocs.boehringer-ingelheim.com/BIWebAccess/
ViewServlet.ser?docBas=renetnt&folderPath=/Prescribing+Information/PIs/Viramune+XR/
ViramuneXR.pdf
103. Nevirapine prescribing information. http://us.viramune.com/index.jsp




105. Case–Control Viramune (Nevirapine) Toxicogenomics Study. www.clinicaltrials.gov/ct2/show/
NCT00310843?term=NCT00310843&rank=1
106. SUSTIVA (efavirenz) prescribing information. http://packageinserts.bms.com/pi/pi_sustiva.pdf
107. Genotype Based Personalized Prescription of Nevirapine (GENPART). www.clinicaltrials.gov/
ct2/show/NCT00986 063?term=NCT00986063&rank=1
Haas et al. Page 9














Overview of nevirapine & its pharmacology
■ Nevirapine is extensively prescribed worldwide to treat HIV-1 infection.
■ Nevirapine has excellent oral bioavailability and distributes widely
throughout the body.
■ Inactivation occurs primarily through hepatic CYP2B6.
■ To decrease likelihood of rash, nevirapine is given at half dose for the first 14
days.
Nevirapine toxicity & human genetics
■ Nevirapine adverse events primarily affect the liver and/or skin.
■ Higher CD4 T-cell count at initiation, female sex and treatment-naive status
confer increased risk.
■ A study from Australia implicated HLA-DRB1*01:01 in hepatic events.
■ Studies in Thailand implicated HLA-Cw*04:01 and HLA-B*35:05 in
cutaneous events.
A study across patient ancestries & toxicity phenotypes
■ A retrospective study enrolled 276 evaluable cases (175 cutaneous events,
101 hepatic events) and 587 evaluable controls of Asian, European and
African descent (hereafter called Asian, white and and black patients).
■ For cutaneous events, the study confirmed associations with HLA-B*35 and
HLA-Cw*04 among Asians, extended the HLA-Cw*04 association to black
and white patients and found a new association between CYP2B6 516G>T.
■ For hepatic events, the study confirmed the association with HLA-DRB1*01.
General considerations for human genetic testing in clinical care
■ Several factors argue strongly against genetic screening to prevent nevirapine
toxicity.
■ Patients at risk can be identified by CD4 T-cell count criteria, and there are
alternatives to nevirapine.
■ Given the potential severity of nevirapine reactions, genetic screening would
have to identify virtually every at-risk patient.
■ In resource-limited countries, public health benefits of genetic screening
would have to be substantial to warrant implementation.
Sensitivity, specificity & clinical consequences of genetic testing with nevirapine
■ The retrospective study mentioned above provides data for considering the
utility of genetic screening.
■ Genetic markers of cutaneous and hepatic events stratified by population
were insensitive.
■ High specificities of some genetic markers likely reflect low allelic
frequencies.
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■ With genetic screening, the number of events still occurring would exceed
those averted, and many patients would needlessly avoid nevirapine.
■ There is no clear benefit of genetic screening at low CD4 T-cell counts.
Conclusion & future perspective
■ Continued research may identify genetic markers with better positive and
negative predictive values.
■ A clinical trial in Thailand is prospectively testing the utility of genetic
screening to prevent nevirapine-associated cutaneous side effects.
■ If useful genetic predictors are found, strategies to implement genetic testing
in resource-limited countries may be warranted.
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HLA-Cw*04 Asian§ 25 (71) 41 (233) 35 (25–47) 82 (77–87) 1.94 (1.53–2.47) 0.78 (0.71–0.88)
Black 15 (27) 15 (77) 56 (37–73) 81 (70–88) 2.95 (2.44–3.56) 0.54 (0.46–0.64)
White 26 (77) 58 (277) 34 (24–45) 79 (74–83) 1.62 (1.28–2.05) 0.84 (0.75–0.93)
HLA-B*35 Asian 14 (71) 15 (227) 20 (12–30) 93 (89–96) 2.86 (1.96–4.16) 0.86 (0.80–0.92)
Black 3 (27) 10 (77) 11 (4–28) 87 (78–93) 0.85 (0.55–1.30) 1.02 (0.97–1.08)
White 21 (77) 48 (277) 27 (19–38) 83 (78–87) 1.59 (1.21–2.09) 0.88 (0.80–0.96)
HLA-Cw*04 and HLA-B*35 Asian 14 (71) 3 (277) 20 (12–30) 99 (96–99.5) 20 (9.51–42) 0.81 (0.75–0.87)
Black 2 (25) 5 (77) 8 (2–25) 94 (86–97) 1.33 (90.77–2.30) 0.98 (0.94–1.02)
White 17 (77) 42 (277) 22 (14–33) 85 (80–89) 1.47 (1.08–2.00) 0.92 (0.85–0.99)
CYP2B6 516TT Asian 10 (52) 20 (222) 19 (11–32) 91 (86–94) 2.11 (1.47–3.03) 0.89 (0.83–0.96)
Black 13 (23) 11 (53) 57 (37–74) 79 (66–88) 2.71 (2.27–3.25) 0.54 (0.46–0.64)
White 7 (47) 13 (271) 15 (7–28) 95 (92–97) 3.00 (1.92–4.69) 0.89 (0.84–0.95)
Hepatic AEs
HLA-DRB1*01 Asian 1 (30) 1 (233) 3 (1–17) 99.6 (98–99.9) 7.50 (1.95–29) 0.97 (0.95–1.00)
Black 2 (14) 8 (77) 14 (4–40) 90 (80–95) 1.40 (0.94–2.09) 0.96 (0.90–1.02)
White 25 (57) 57 (277) 44 (32–57) 79 (74–84) 2.10 (1.70–2.58) 0.71 (0.62–0.81)
Sensitivity was calculated as (true-positive tests)/(total patients with AEs). Specificity was calculated as (true-negative tests)/(total patients without
AEs). Positive and negative likelihood ratios were based on a population of 1000 patients. Positive likelihood ratios were calculated as (sensitivity)/
(1−specificity). Negative likelihood ratios were calculated as (specificity)/(1−sensitivity).
AE: Adverse event.
†
All calculations are based on data in Yuan et al. [22].
‡
Confidence intervals were calculated with a Bayesian method [26].
§
Among the Asian population, 74% were Thai.
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Hypothetical population in which 5% would have AE without genetic screening: cutaneous AEs
HLA-Cw*04 Asian†‡ 9.5 (5.4–16.0) 96.0 (95.1–96.9) 18 (13–24) 32 (27–38) 185 (130–236) 10.5 (5.5–18.9) 57 (43–80)
Black 13.1 (6.1–24.3) 97.2 (95.5–98.4) 28 (19–37) 22 (14–32) 213 (119–308) 7.7 (3.3–16.6) 36 (27–54)
White 7.8 (4.6–12.2) 95.8 (94.9–96.6) 17 (12–23) 33 (28–38) 216 (168–264) 12.8 (7.5–22.0) 59 (44–83)
HLA-B*35 Asian†‡ 13.6 (5.4–28.3) 95.7 (95.1–96.3) 10 (6–15) 40 (35–44) 73 (42–118) 7.4 (2.8–19.6) 101 (67–167)
Black 4.3 (0.9–17.4) 94.9 (93.9–96.1) 6 (2–14) 44 (36–48) 129 (68–222) 23.2 (4.9–111.2) 180 (71–500)
White 7.6 (4.3–13.3) 95.6 (93.9–96.1) 14 (9–19) 36 (31–41) 178 (129–224) 13.1 (6.8–23.6) 73 (53–105)
HLA-Cw*04 and HLA-B*35 Asian 44.0 (13.6–75.9) 95.9 (95.4–96.4) 10 (6–15) 40 (35–44) 22 (9–51) 2.3 (0.6–8.5) 101 (67–167)
Black 6.1 (0.7–30.5) 95.1 (94.3–96.1) 4 (1–13) 46 (38–49) 66 (29–145) 16.4 (2.3–145.3) 250 (80–1000)
White 7.1 (3.6–13.6) 95.4 (94.6–96.2) 11 (7–17) 39 (34–43) 155 (109–204) 14.0 (6.6–29.2) 91 (61–143)
CYP2B6 516TT Asian 10.1 (4.0–21.9) 95.5 (94.8–96.3) 10 (6–16) 40 (34–45) 95 (61–147) 9.9 (3.8–26.8) 104 (63–182)
Black 12.5 (5.4–24.5) 97.2 (95.2–98.5) 28 (19–37) 22 (13–32) 225 (119–346) 8.0 (3.2–18.7) 35 (27–54)
White 14.0 (4.4–32.9) 95.5 (94.9–96.2) 7 (4–14) 43 (36–47) 53 (31–89) 7.1 (2.2–25.4) 134 (71–286)
Hypothetical population in which 5% would have AE without genetic screening: hepatic AEs
HLA-DRB1*01 Asian 29.0 (2.6–89.9) 95.1 (95.0–95.8) 2 (1–9) 48 (42–50) 6 (1.4–27) 3.4 (0.2–54.8) 600 (118–2000)
Black 6.7 (1.0–29.6) 95.2 (94.1–96.8) 7 (2–20) 43 (30–48) 106 (49–209) 14.8 (2.4–104.6) 140 (50–500)
White 10.1 (6.1–15.8) 96.4 (95.4–97.4) 22 (16–29) 28 (22–34) 217 (159–266) 9.9 (5.6–16.6) 46 (35–63)
Hypothetical population in which 20% would have AE without genetic screening: cutaneous AEs
HLA-Cw*04 Asian 33.3 (21.4–47.5) 83.6 (80.4–86.8) 70 (50–94) 130 (106–150) 211 (131–255) 3.0 (1.4–5.1) 14 (11–20)
Black 41.6 (23.6–60.3) 87.9 (81.6–92.9) 111 (74–146) 89 (54–126) 267 (116–332) 2.4 (0.8–4.5) 9 (7–14)
White 28.7 (18.8–39.8) 82.7 (79.6–85.8) 68 (48–90) 133 (110–152) 235 (162–276) 3.5 (1.8–5.8) 15 (11–21)
HLA-B*35 Asian†‡ 42.7 (21.4–65.2) 82.3 (80.2–84.6) 39 (24–60) 161 (140–176) 92 (49–141) 2.3 (0.8–5.9) 25 (17–42)
Black 17.6 (4.3–50.0) 79.7 (76.5–83.8) 22 (8–56) 178 (144–192) 126 (62–230) 5.7 (1.1–28.7) 45 (18–125)
White 28.2 (17.8–42.2) 82.0 (79.4–84.9) 55 (38–76) 146 (124–162) 193 (128–238) 3.5 (1.7–6.3) 18 (13–26)
HLA-Cw*04 and HLA-B*35 Asian 78.9 (42.9–93.8) 83.1 (81.4–85.0) 39 (24–60) 161 (140–176) 50 (21–85) 1.3 (0.3–3.5) 25 (17–42)
Black 23.5 (3.4–67.6) 80.3 (77.8–83.8) 16 (4–50) 184 (150–196) 68 (27–161) 4.2 (0.5–40.3) 63 (20–250)
White 26.7 (14.9–42.9) 81.3 (78.8–84.2) 44 (28–66) 156 (134–172) 166 (107–217) 3.7 (1.6–7.7) 23 (15–36)
CYP2B6 516TT Asian 34.8 (16.4–57.1) 81.8 (79.4–84.7) 39 (22–64) 162 (136–178) 111 (63–169) 2.9 (1.0–7.7) 26 (16–45)
Black 40.5 (21.4–60.7) 87.9 (80.7–93.1) 113 (74–148) 87 (52–126) 279 (115–365) 2.5 (0.8–4.9) 9 (7–14)
White 43.7 (17.9–70.0) 81.7 (79.8–84.3) 30 (14–56) 170 (144–186) 68 (34–116) 2.3 (0.6–8.3) 34 (18–71)
Hypothetical population in which 20% would have AE without genetic screening: hepatic AEs
HLA-DRB1*01 Asian 66.0 (11.1–97.7) 80.5 (79.8–82.8) 7 (2–34) 193 (166–198) 10 (2–50) 1.5 (0.1–24.8) 150 (29–500)

















































Black 25.6 (4.8–66.7) 80.7 (76.9–86.4) 29 (8–80) 171 (120–192) 112 (45–237) 3.9 (0.6–29.6) 35 (13–125)
White 34.8 (23.5–47.1) 85.0 (81.3–88.7) 88 (64–114) 112 (86–136) 252 (156–286) 2.9 (1.4–4.5) 11 (9–16)
This table considers hypothetical populations of 1000 individuals, all of whom initiate nevirapine-containing regimens at higher CD4 T-cell counts.
Within each population hypothetical scenarios were examined in which, without genetic screening, either 5 or 20% of individuals would experience




All calculations are based on data in Yuan et al. [22].
‡
Positive predictive value was calculated as ([number of individuals per 100 that would have the AE without genetic testing] × [genetic test
sensitivity])/([number of individuals per 100 that would not have the AE without genetic testing] × [1−(genetic test specificity)]).
§
Negative predictive value was calculated as ([number of individuals per 100 that would not have the AE without genetic testing] × [genetic test
specificity])/([(number of individuals per 100 that would not have the AE without genetic testing) × (genetic test specificity)] + [(number of
individuals per 100 that would not have the AE without genetic testing) × (1-genetic test sensitivity)]).
¶
Number of nevirapine-associated AEs that would be prevented by genetic screening; AEs still occurring: number of nevirapine-associated AEs
that would still occur (i.e., among individuals without the genetic marker); avoidance of nevirapine: number of individuals who would be
prescribed an antiretroviral other than nevirapine; needless avoidance of nevirapine: for each nevirapine-associated AEs prevented, how many
individuals would receive a different antiretroviral but could have safely received nevirapine.
#
Avoidance of nevirapine (per AE averted) was calculated as ([number of AEs that would occur per 1000 if genetic testing were not done] ×
[genetic test sensitivity/([(1 −genetic test specificity) × (1000 × [number of individuals per 100 that would not have the AE without genetic
testing])/100]).
††
Among the Asian population, 74% were Thai.
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